Home LiteratureArticle Details
PMID: 10874060 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

The New England journal of medicine ·Vol. 342 ·No. 26 ·2000-06-29 ·Pages 1930-6

Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI

Abstract

Children with gastrointestinal infections caused by Escherichia coli O157:H7 are at risk for the hemolytic-uremic syndrome. Whether antibiotics alter this risk is unknown. We conducted a prospective cohort study of 71 children younger than 10 years of age who had diarrhea caused by E. coli O157:H7 to assess whether antibiotic treatment in these children affects the risk of the hemolytic-uremic syndrome and to assess the influence of confounding factors on this outcome. Estimates of relative risks were adjusted for possible confounding effects with the use of logistic-regression analysis. Among the 71 children, 9 (13 percent) received antibiotics and the hemolytic-uremic syndrome developed in 10 (14 percent). Five of these 10 children had received antibiotics. Factors significantly associated with the hemolytic-uremic syndrome were a higher initial white-cell count (relative risk, 1.3; 95 percent confidence interval, 1.1 to 1.5), evaluation with stool culture soon after the onset of illness (relative risk, 0.3; 95 percent confidence interval, 0.2 to 0.8), and treatment with antibiotics (relative risk, 14.3; 95 percent confidence interval, 2.9 to 70.7). The clinical and laboratory characteristics of the 9 children who received antibiotics and the 62 who did not receive antibiotics were similar. In a multivariate analysis that was adjusted for the initial white-cell count and the day of illness on which stool was obtained for culture, antibiotic administration remained a risk factor for the development of the hemolytic uremic syndrome (relative risk, 17.3; 95 percent confidence interval, 2.2 to 137). Antibiotic treatment of children with E. coli O157:H7 infection increases the risk of the hemolytic-uremic syndrome.

MeSH Terms
Anti-Bacterial Agents/adverse effects,therapeutic use Cephalosporins/adverse effects Child Child, Preschool Diarrhea/complications,drug therapy,microbiology Escherichia coli Infections/complications,drug therapy,microbiology Escherichia coli O157 Feces/microbiology Female Hemolytic-Uremic Syndrome/etiology Humans Infant Logistic Models Male Prospective Studies Risk Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects
Chemicals
Anti-Bacterial Agents Cephalosporins Trimethoprim, Sulfamethoxazole Drug Combination
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Wong C S
Children's Hospital and Regional Medical Center and the University of Washington School of Medicine, Seattle 98105, USA.
Jelacic S
Habeeb R L
Watkins S L
Tarr P I
References (32)
32 references, click to expand
  1. Sorbitol-MacConkey medium for detection of Escherichia coli O157:H7 associated with hemorrhagic colitis.
    J Clin Microbiol. 1986 May;23(5):869-72 PMID: 3519658
  2. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.
    J Infect Dis. 1985 May;151(5):775-82 PMID: 3886804
  3. A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home.
    N Engl J Med. 1987 Dec 10;317(24):1496-500 PMID: 3317047
  4. Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance.
    JAMA. 1989 Jul 21;262(3):355-9 PMID: 2661870
  5. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults.
    Arch Intern Med. 1990 Mar;150(3):541-6 PMID: 2178582
  6. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations.
    J Pediatr. 1990 Apr;116(4):544-51 PMID: 2181098
  7. Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome.
    J Pediatr. 1990 Apr;116(4):589-92 PMID: 2181099
  8. Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology.
    J Infect Dis. 1990 Aug;162(2):553-6 PMID: 2197346
  9. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I.
    Infection. 1992 Jan-Feb;20(1):25-9 PMID: 1563808
  10. Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group.
    Ann Intern Med. 1992 Aug 1;117(3):202-8 PMID: 1616214
  11. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis.
    J Pediatr. 1992 Aug;121(2):299-303 PMID: 1640303
  12. Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome.
    Pediatrics. 1992 Oct;90(4):616-21 PMID: 1408519
  13. A continuing assessment of risk factors for the development of Escherichia coli O157:H7-associated hemolytic uremic syndrome.
    Clin Nephrol. 1994 Aug;42(2):85-9 PMID: 7955583
  14. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin.
    Clin Infect Dis. 1996 Jun;22(6):1019-25 PMID: 8783703
  15. [The old and new problems of the antibiotics treatment in hemorrhagic enterocolitis and hemolytic uremic syndrome, according to Japanese epidemiological studies].
    Nihon Rinsho. 1997 Mar;55(3):706-14 PMID: 9086785
  16. [Initial treatment at an outbreak of E. coli O-157:H7 infection: especially with respect to therapy in the emergency].
    Jpn J Antibiot. 1997 Oct;50(10):821-8 PMID: 9412872
  17. [Report of questionnaire about enterohemorrhagic Escherichia coli cases caused in the area including Sakai City in 1996].
    Kansenshogaku Zasshi. 1997 Nov;71(11):1144-54 PMID: 9455055
  18. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States.
    J Infect Dis. 1998 Apr;177(4):962-6 PMID: 9534969
  19. [Retrospective analysis of the relationship between HUS incidence and antibiotics among patients with Escherichia coli O157 enterocolitis in the Sakai outbreak].
    Kansenshogaku Zasshi. 1998 Mar;72(3):266-72 PMID: 9643979
  20. Risk of hemolytic uremic syndrome after sporadic Escherichia coli O157:H7 infection: results of a Canadian collaborative study. Investigators of the Canadian Pediatric Kidney Disease Research Center.
    J Pediatr. 1998 May;132(5):777-82 PMID: 9602185
  21. [Predictive factors for development of hemolytic uremic syndrome (HUS) and early intensive treatments for prevention of HUS enterohemorrhagic Escherichia coli infection].
    Jpn J Antibiot. 1997 Nov;50(11):855-61 PMID: 9651603
  22. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections.
    Pediatrics. 1997 Jul;100(1):E12 PMID: 9200386
  23. [The drug sensitivity of enterohemorragic Escherichia coli and antibiotics treatment for hemorrhagic enterocolitis--from an outbreak of enterocolitis in Sakai city].
    Jpn J Antibiot. 1997 Jul;50(7):591-6 PMID: 9743905
  24. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents.
    Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):761-6 PMID: 9923515
  25. Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City, 1996.
    Pediatr Int. 1999 Apr;41(2):213-7 PMID: 10221032
  26. Risk factors for the development of Escherichia coli O157:H7 associated with hemolytic uremic syndrome.
    Pediatr Int. 1999 Apr;41(2):218-22 PMID: 10221033
  27. Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7.
    Pediatr Int. 1999 Apr;41(2):228-32 PMID: 10221035
  28. Induction of type 2 Shiga toxin synthesis in Escherichia coli O157 by 4-quinolones.
    Lancet. 1999 May 8;353(9164):1588-9 PMID: 10334263
  29. Escherichia coli O157:H7 diarrhea in a nursing home: clinical, epidemiological, and pathological findings.
    J Infect Dis. 1986 Oct;154(4):631-8 PMID: 3528316
  30. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.
    Lancet. 1983 Mar 19;1(8325):619-20 PMID: 6131302
  31. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection.
    Clin Nephrol. 1999 Dec;52(6):357-62 PMID: 10604643
  32. Failure of pre-diarrheal antibiotics to prevent hemolytic uremic syndrome in serologically proven Escherichia coli O157:H7 gastrointestinal infection.
    J Pediatr. 1999 Dec;135(6):768-9 PMID: 10586184
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
0028-4793
Published
2000-06-29
Pages
1930-6
Language
English
Region
United States
NLM ID
0255562
PMCID
PMC3659814
Subset
IM
Grants
NIDDK NIH HHS · R01 DK052081 · United States
NIDDK NIH HHS · 1RO1DK52081 · United States
Corrections
CommentIn
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com